[{"name":"ICB_Braun","doi":"10.5281/zenodo.7332074","downloadLink":"https://zenodo.org/record/7332074/files/ICB_Braun.rds?download=1","dateCreated":"2022-11-18T01:29:17.286Z","dataset":{"name":"ICB_Braun","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Braun, d.a., et al., interplay of somatic alterations and immune infiltration modulates response to pd-1 blockade in advanced clear cell renal cell carcinoma. nat med, 2020. 26(6): p. 909-918.","link":"https://pubmed.ncbi.nlm.nih.gov/32472114/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""},{"name":"snv","genomeType":"DNA","source":""}]},{"name":"ICB_Padron","doi":"10.5281/zenodo.7332212","downloadLink":"https://zenodo.org/record/7332212/files/ICB_Padron.rds?download=1","dateCreated":"2022-11-18T02:49:35.166Z","dataset":{"name":"ICB_Padron","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Padrón, Lacey J. et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine, June 3, 2022.","link":"https://www.nature.com/articles/s41591-022-01829-9"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA"}]},{"name":"ICB_Shiuan","doi":"10.5281/zenodo.7332259","downloadLink":"https://zenodo.org/record/7332259/files/ICB_Shiuan.rds?download=1","dateCreated":"2022-11-18T03:15:33.110Z","dataset":{"name":"ICB_Shiuan","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Shiuan E., et al., clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel). 2021 Mar 23;13(6):1475. doi: 10.3390/cancers13061475. PMID: 33806963; PMCID: PMC8004696.","link":"https://pubmed.ncbi.nlm.nih.gov/33806963/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Kim","doi":"10.5281/zenodo.7332153","downloadLink":"https://zenodo.org/record/7332153/files/ICB_Kim.rds?download=1","dateCreated":"2022-11-18T02:18:22.994Z","dataset":{"name":"ICB_Kim","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Kim ST., et al., Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16. PMID: 30013197.","link":"https://pubmed.ncbi.nlm.nih.gov/30013197/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_VanDenEnde","doi":"10.5281/zenodo.7332295","downloadLink":"https://zenodo.org/record/7332295/files/ICB_VanDenEnde.rds?download=1","dateCreated":"2022-11-18T03:31:52.174Z","dataset":{"name":"ICB_VanDenEnde","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"van den Ende T., et al., Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. PMID: 33504550.","link":"https://pubmed.ncbi.nlm.nih.gov/33504550/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Liu","doi":"10.5281/zenodo.7332172","downloadLink":"https://zenodo.org/record/7332172/files/ICB_Liu.rds?download=1","dateCreated":"2022-11-18T02:26:27.401Z","dataset":{"name":"ICB_Liu","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Liu, d., et al., integrative molecular and clinical modeling of clinical outcomes to pd1 blockade in patients with metastatic melanoma. nat med, 2019. 25(12): p. 1916-1927.","link":"https://pubmed.ncbi.nlm.nih.gov/31792460/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""},{"name":"snv","genomeType":"DNA","source":""},{"name":"cna","genomeType":"DNA","source":""}]},{"name":"ICB_Snyder","doi":"10.5281/zenodo.7332266","downloadLink":"https://zenodo.org/record/7332266/files/ICB_Snyder.rds?download=1","dateCreated":"2022-11-18T03:20:08.482Z","dataset":{"name":"ICB_Snyder","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Snyder, a., et al., contribution of systemic and somatic factors to clinical response and resistance to pd-l1 blockade in urothelial cancer: an exploratory multi-omic analysis. plos med, 2017. 14(5): p. e1002309.","link":"https://pubmed.ncbi.nlm.nih.gov/28552987/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Riaz","doi":"10.5281/zenodo.7332230","downloadLink":"https://zenodo.org/record/7332230/files/ICB_Riaz.rds?download=1","dateCreated":"2022-11-18T03:03:06.153Z","dataset":{"name":"ICB_Riaz","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Riaz, N., et al. 2015. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017. 171(4): p.934-949.e16.","link":"https://pubmed.ncbi.nlm.nih.gov/29033130/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA"},{"name":"snv","genomeType":"DNA"}]},{"name":"ICB_Jerby_Arnon","doi":"10.5281/zenodo.7332119","downloadLink":"https://zenodo.org/record/7332119/files/ICB_Jerby_Arnon.rds?download=1","dateCreated":"2022-11-18T02:04:11.131Z","dataset":{"name":"ICB_Jerby_Arnon","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Jerby-arnon, L., et al. 2018. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018. 175(4): p.984-997.e24.","link":"https://pubmed.ncbi.nlm.nih.gov/30388455/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Nathanson","doi":"10.5281/zenodo.7332207","downloadLink":"https://zenodo.org/record/7332207/files/ICB_Nathanson.rds?download=1","dateCreated":"2022-11-18T02:43:58.490Z","dataset":{"name":"ICB_Nathanson","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Nathanson, t., et al., somatic mutations and neoepitope homology in melanomas treated with ctla-4 blockade. cancer immunol res, 2017. 5(1): p. 84-91.","link":"https://pubmed.ncbi.nlm.nih.gov/27956380/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""},{"name":"snv","genomeType":"DNA","source":""}]},{"name":"ICB_Miao1","doi":"10.5281/zenodo.7332188","downloadLink":"https://zenodo.org/record/7332188/files/ICB_Miao1.rds?download=1","dateCreated":"2022-11-18T02:38:02.212Z","dataset":{"name":"ICB_Miao1","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Miao, D., et al. 2018. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018. 359(6377): p.801-806.","link":"https://pubmed.ncbi.nlm.nih.gov/29301960/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""},{"name":"snv","genomeType":"DNA","source":""}]},{"name":"ICB_Hugo","doi":"10.5281/zenodo.7332108","downloadLink":"https://zenodo.org/record/7332108/files/ICB_Hugo.rds?download=1","dateCreated":"2022-11-18T01:53:06.414Z","dataset":{"name":"ICB_Hugo","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Hugo, w., et al., genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma. cell, 2016. 165(1): p. 35-44.","link":"https://pubmed.ncbi.nlm.nih.gov/26997480/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Puch","doi":"10.5281/zenodo.7332226","downloadLink":"https://zenodo.org/record/7332226/files/ICB_Puch.rds?download=1","dateCreated":"2022-11-18T02:56:55.168Z","dataset":{"name":"ICB_Puch","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Cui C., et al., Ratio of the interferon-? signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. NPJ Genom Med. 2021 Feb 4;6(1):7. doi: 10.1038/s41525-021-00169-w. PMID: 33542239; PMCID: PMC7862369.","link":"https://pubmed.ncbi.nlm.nih.gov/33542239/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Limagne1","doi":"10.5281/zenodo.7458950","downloadLink":"https://zenodo.org/record/7458950/files/ICB_Limagne1.rds?download=1","dateCreated":"2022-12-19T22:36:46.186Z","dataset":{"name":"ICB_Limagne1","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Limagne, Emeric et al. “MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.” Cancer cell vol. 40,2 (2022): 136-152.e12. doi:10.1016/j.ccell.2021.12.009","link":"https://pubmed.ncbi.nlm.nih.gov/35051357/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":null}]},{"name":"ICB_Roh","doi":"10.5281/zenodo.7332236","downloadLink":"https://zenodo.org/record/7332236/files/ICB_Roh.rds?download=1","dateCreated":"2022-11-18T03:08:15.096Z","dataset":{"name":"ICB_Roh","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Roh, W., et al. 2017. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med, 2017. 9(379).","link":"https://pubmed.ncbi.nlm.nih.gov/28251903/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA"},{"name":"snv","genomeType":"DNA","source":""}]},{"name":"ICB_Hwang","doi":"10.5281/zenodo.7332114","downloadLink":"https://zenodo.org/record/7332114/files/ICB_Hwang.rds?download=1","dateCreated":"2022-11-18T01:58:50.531Z","dataset":{"name":"ICB_Hwang","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Hwang, S., et al. 2020. Immune gene signatures for predicting durable clinical benefit of anti-pd-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep, 2020. 10(1): p.643.","link":"https://pubmed.ncbi.nlm.nih.gov/31959763/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Van_Allen","doi":"10.5281/zenodo.7332289","downloadLink":"https://zenodo.org/record/7332289/files/ICB_Van_Allen.rds?download=1","dateCreated":"2022-11-18T03:26:52.090Z","dataset":{"name":"ICB_Van_Allen","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Van allen, e.m., et al., genomic correlates of response to ctla-4 blockade in metastatic melanoma. science, 2015. 350(6257): p. 207-211.","link":"https://pubmed.ncbi.nlm.nih.gov/26359337/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""},{"name":"snv","genomeType":"DNA","source":""},{"name":"cna","genomeType":"DNA","source":""}]},{"name":"ICB_Jung","doi":"10.5281/zenodo.7332134","downloadLink":"https://zenodo.org/record/7332134/files/ICB_Jung.rds?download=1","dateCreated":"2022-11-18T02:11:01.480Z","dataset":{"name":"ICB_Jung","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Jung, H., et al. 2019. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun, 2019. 10(1): p.4278.","link":"https://pubmed.ncbi.nlm.nih.gov/31537801/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""},{"name":"snv","genomeType":"DNA","source":""}]},{"name":"ICB_Gide","doi":"10.5281/zenodo.7332096","downloadLink":"https://zenodo.org/record/7332096/files/ICB_Gide.rds?download=1","dateCreated":"2022-11-18T01:42:51.862Z","dataset":{"name":"ICB_Gide","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Gide TN., et al., Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003. PMID: 30753825.","link":"https://pubmed.ncbi.nlm.nih.gov/30753825/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""}]},{"name":"ICB_Limagne2","doi":"10.5281/zenodo.7458956","downloadLink":"https://zenodo.org/record/7458956/files/ICB_Limagne2.rds?download=1","dateCreated":"2022-12-19T22:54:28.577Z","dataset":{"name":"ICB_Limagne2","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Limagne, Emeric et al. “MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.” Cancer cell vol. 40,2 (2022): 136-152.e12. doi:10.1016/j.ccell.2021.12.009","link":"https://pubmed.ncbi.nlm.nih.gov/35051357/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":null}]},{"name":"ICB_Mariathasan","doi":"10.5281/zenodo.7332183","downloadLink":"https://zenodo.org/record/7332183/files/ICB_Mariathasan.rds?download=1","dateCreated":"2022-11-18T02:33:35.528Z","dataset":{"name":"ICB_Mariathasan","versionInfo":{"version":"1.0","type":null,"publication":[{"citation":"Mariathasan, s., et al., tgf? attenuates tumour response to pd-l1 blockade by contributing to exclusion of t cells. nature, 2018. 554(7693): p. 544-548.","link":"https://pubmed.ncbi.nlm.nih.gov/29443960/"}]}},"availableDatatypes":[{"name":"rnaseq","genomeType":"RNA","source":""},{"name":"snv","genomeType":"DNA","source":""},{"name":"cna","genomeType":"DNA","source":""}]}]